Ferritin Decorated PLGA/Paclitaxel Loaded Nanoparticles Endowed with an Enhanced Toxicity Toward MCF‑7 Breast Tumor Cells

• Published in: Bioconjugate chemistry Vol. 28; no. 4; pp. 1283 - 1290
• Main Authors: Turino, Ludmila N, Ruggiero, Maria R, Stefanìa, Rachele, Cutrin, Juan C, Aime, Silvio, Geninatti Crich, Simonetta
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 19.04.2017
• Subjects: Albumin; Antineoplastic Agents, Phytogenic - administration & dosage; Breast cancer; Breast Neoplasms - diagnostic imaging; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Cells; Contrast Media - administration & dosage; Contrast Media - pharmacokinetics; Cytotoxicity; Drug Carriers - chemistry; Drug Delivery Systems - methods; Ferritin; Ferritins - chemistry; Glycolic acid; Humans; Magnetic Resonance Imaging; MCF-7 Cells; Nanoparticles; Nanoparticles - chemistry; Nanoparticles - therapeutic use; Paclitaxel; Paclitaxel - administration & dosage; Paclitaxel - pharmacokinetics; Polyglycolic Acid - chemistry; Polylactide-co-glycolide; Proteins; Scavenger Receptors, Class A; Toxicity; Tumor cells; Tumors
• ISSN: 1043-1802; 1520-4812
• DOI: 10.1021/acs.bioconjchem.7b00096

Polylactic and glycolic acid nanoparticles (PLGA-NPs), coated with L-ferritin, are exploited for the simultaneous delivery of paclitaxel and an amphiphilic Gd based MRI contrast agent into breast cancer cells (MCF7). L-ferritin has been covalently conjugated to the external surface of PLGA-NPs exploiting NHS activated carboxylic groups. The results confirmed that nanoparticles decorated with L-ferritin have many advantages with respect to both albumin-decorated and nondecorated particles. Ferritin moieties endow PLGA-NPs with targeting capability, exploiting SCARA5 receptors overexpressed by these tumor cells, that results in an increased paclitaxel cytotoxicity. Moreover, protein coating increased nanoparticle stability, thus reducing the fast and aspecific drug release before reaching the target. The theranostic potential of the nanoparticles has been demonstrated by evaluating the signal intensity enhancement on T1-weighted MRI images of labeled MCF7 cells. The results were compared with that obtained with MDA cells used as negative control due to their lower SCARA5 expression.